Specialty Pharmaceutical Company dedicated to patients living with chronic conditions

Filing date Description Form Filing Group Filer View

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000020.pdf 0001103021-19-000020.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Sirgo Mark A 0001103021-19-000021.pdf 0001103021-19-000021.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000017.pdf 0001103021-19-000017.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Sirgo Mark A 0001103021-19-000015.pdf 0001103021-19-000015.rtf View HTML

EFFECT

EFFECT
Other
9999999995-19-002089.pdf 9999999995-19-002089.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
ODONNELL FRANCIS E JR 0001103021-19-000011.pdf 0001103021-19-000011.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Broadfin Capital, LLC 0001103021-19-000008.pdf 0001103021-19-000008.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Greenleaf Peter 0001103021-19-000006.pdf 0001103021-19-000006.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Watson W. Mark 0001103021-19-000009.pdf 0001103021-19-000009.rtf View HTML

Statement of changes in beneficial ownership of securities

4
3,4,5
Davis Todd C 0001103021-19-000007.pdf 0001103021-19-000007.rtf View HTML

Copyright Morningstar

BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
Thank you. We will get back to you soon